NCT03447314: Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors

NCT03447314
Breast Cancer Type: HER2+, HR+ & HER2-negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Breast cancer patients will not be eligible for Part 2
Exclusions: Triple Negative, Symptomatic central nervous system (CNS) metastases- see trial for details
https://ClinicalTrials.gov/show/NCT03447314

Comments are closed.

Up ↑